Sugi Predict

Sugi Predict / Compounds / SCHEMBL1783731

SCHEMBL1783731

SCHEMBL1783731

CCCCC(CC=O)OC

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CA2 P00918 3/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CTSK P43235 4/20 0.35
▸ ACHE P22303 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ ADH1B P00325 1/20 0.31
▸ ADH1C P00326 1/20 0.31
▸ ADH1A P07327 1/20 0.31
▸ ADH4 P08319 1/20 0.31
▸ ADH7 P40394 1/20 0.31
▸ FAAH O00519 2/20 0.31
▸ CYP3A4 P08684 2/20 0.31
▸ TRPV1 Q8NER1 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ FDPS P14324 1/20 0.31
▸ DNM1 Q05193 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1783633 0.94 ADH1B (0.38) TSHRSMN1; SMN2CA2CA1ADH1B
SCHEMBL1784353 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1785652 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL997242 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1783325 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1784237 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1712462 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1782016 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1786362 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C
SCHEMBL1783586 0.92 TSHR (0.41) TSHRCA2CA1ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8632792-B2 Cooling sensation agent composition and sensory stimulation agent composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-01-21 — — US disclosed
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-05-19 — — US disclosed
WO-2009123355-A2 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-10-08 — — WO disclosed
EP-1212339-B1 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS ISIS PHARMACEUTICALS INC (US) 2008-12-31 — — EP disclosed
EP-1496943-A4 OLIGOMERIC COMPOUNDS HAVING MODIFIED PHOSPHATE GROUPS ISIS PHARMACEUTICALS INC (US) 2007-05-23 — — EP disclosed
US-6991902-B2 Nucleobase heterocyclic combinatorialization ISIS PHARMACEUTICALS, INC. (US) 2006-01-31 — — US disclosed
US-6942966-B1 libraries formed by permutations; combinatorial chemistry; drug screening ISIS PHARMACEUTICALS, INC. (US) 2005-09-13 — — US disclosed
US-6933288-B2 Pyranosyl cytosines: pharmaceutical formulations and methods ISIS PHARMACEUTICALS, INC. 2005-08-23 — — US disclosed
EP-1223173-B1 Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof ISIS PHARMACEUTICALS INC (US) 2005-07-13 — — EP disclosed
US-20050106598-A1 Novel peptide-conjugated oligomeric compounds ISIS PHARMACEUTICALS, INC. 2005-05-19 — — US disclosed
EP-0651759-A4 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. ISIS PHARMACEUTICALS INC (US) 1995-10-25 — — EP disclosed
WO-1995023160-A1 NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1995-08-31 — — WO disclosed
WO-1995021184-A1 SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING ISIS PHARMACEUTICALS, INC. (US) 1995-08-10 — — WO disclosed
WO-1995018623-A1 OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES ISIS PHARMACEUTICALS, INC. (US) 1995-07-13 — — WO disclosed
WO-1995018792-A1 PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS ISIS PHARMACEUTICALS, INC. (US) 1995-07-13 — — WO disclosed
WO-1995018820-A1 MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 1995-07-13 — — WO disclosed
EP-0651759-A1 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF ISIS PHARMACEUTICALS, INC. (US) 1995-05-10 — — EP disclosed
EP-0635023-A1 COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1995-01-25 — — EP disclosed
WO-1994002501-A1 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF ISIS PHARMACEUTICALS, INC. (US) 1994-02-03 — — WO disclosed
WO-1993018052-A1 COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1993-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TRPA1, HRH1, HRH2 TSHR 2479/4885SMN1; SMN2 2144/4885CA2 3566/4885
US-20050106598-A1 Novel peptide-conjugated oligomeric compounds IAPP, NGLY1, TAP1 TSHR 2982/4885SMN1; SMN2 3698/4885CA2 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.